- Home
- OP vs CERO Comparison
OP vs CERO Comparison
Compare OP & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- CERO
- Stock Information
- Founded
- OP 2021
- CERO 2017
- Country
- OP Greece
- CERO United States
- Employees
- OP N/A
- CERO N/A
- Industry
- OP
- CERO
- Sector
- OP
- CERO
- Exchange
- OP Nasdaq
- CERO Nasdaq
- Market Cap
- OP 5.3M
- CERO 3.5M
- IPO Year
- OP N/A
- CERO N/A
- Fundamental
- Price
- OP $1.84
- CERO $9.79
- Analyst Decision
- OP
- CERO Strong Buy
- Analyst Count
- OP 0
- CERO 2
- Target Price
- OP N/A
- CERO $45.00
- AVG Volume (30 Days)
- OP 9.3M
- CERO 3.3M
- Earning Date
- OP 08-06-2025
- CERO 08-13-2025
- Dividend Yield
- OP N/A
- CERO N/A
- EPS Growth
- OP N/A
- CERO N/A
- EPS
- OP N/A
- CERO N/A
- Revenue
- OP $25,702,000.00
- CERO N/A
- Revenue This Year
- OP N/A
- CERO N/A
- Revenue Next Year
- OP N/A
- CERO N/A
- P/E Ratio
- OP N/A
- CERO N/A
- Revenue Growth
- OP 35.58
- CERO N/A
- 52 Week Low
- OP $0.63
- CERO $6.71
- 52 Week High
- OP $3.17
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- OP 55.66
- CERO 50.09
- Support Level
- OP $1.82
- CERO $8.12
- Resistance Level
- OP $2.30
- CERO $13.14
- Average True Range (ATR)
- OP 0.51
- CERO 2.83
- MACD
- OP 0.02
- CERO 0.39
- Stochastic Oscillator
- OP 46.59
- CERO 19.58
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.